



Attorney Docket No: 1216-1-006/CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Richard N. Kolesnick et al.

SERIAL NO: 10/727,358

EXAMINER: Brian A. Whiteman

DATE FILED: December 3, 2003

ART UNIT: 1635

FOR: KINASE SUPPRESSOR OF RAS INACTIVATION FOR THERAPY OF
RAS MEDIATED TUMORIGENESIS

CERTIFICATE OF MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 13, 2006.

Pamela De Marco
(Name of depositor)


(Signature and Date)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97, Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References AA through DW listed on the attached Form PTO-1449. Since this Information Disclosure Statement is filed after mailing of the First Office Action, but prior to mailing of a Final Office Action or Notice of Allowance, a check in the amount of \$180.00 is included to cover the fee due pertinent to C.F.R. 37 §1.97(c). Please charge any additional fees, or credit any overpayments, to Deposit Account 11-1153.

Respectfully submitted,



Christine E. Dietzel, Ph.D.
Agent for Applicants
Registration No. 37,309

10/17/2006 TTRAN1 00000014 10727358

01 FC:1806

180.00 OP

KLAUBER & JACKSON, LLC.
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800
Date: October 13, 2006

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office 		ATTORNEY DOCKET NO.	1216-1-006/CIP
		SERIAL NO.	10/727,358
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	Richard N. Kolesnick, et al.
		FILING DATE	December 3, 2003
		GROUP	1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA	6,416,951	7/9/02	Schmidt et al.			
	AB	6,500,615	12/31/02	Schmidt et. al.			
	AC	6,277,981	8/21/01	Tu et al.			
	AD	5, 591,721	1/7/97	Agrawal et al.			
	AE	2003/0109466	6/12/03	Monia et al.			
	AF	5,747,288	5/5/98	Rubin et al.			
	AG	5,700,675	12/23/97	Rubin et al.			
	AH	5,747,275	5/5/98	Rubin et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
	BA	US03/16961	5/29/03	PCT			
	BB	WO97/21820	6/19/97	Rubin et al.			

EXAMINER:	DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	1216-1-006/CIP
	SERIAL NO.	10/727,358
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Richard N. Kolesnick, et al.
	FILING DATE	December 3, 2003
	GROUP	1635

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Agrawal, S., Temsamani, J. & Tang, J.Y. (1991) Proc. Natl. Acad Sci U.S.A. 88:7595-7599
CB	Almoguera, C. et al (1988) Cell. 53:549-554
CC	Balaban, N. et al. (1996) Biochim Biophys Acta. 1314:147-156
CD	Banerjee, D. (2001) Curr Opin Investig Drugs 2:574-580
CE	Bennett et al. (1994) J. Immunol. 152:3530-3540
CF	Bernhard, E.J. et al. (1998) Cancer Res. 58:1754-1761
CG	Bernhard, E.J. et al. (2000) Cancer Res. 60:6597-6600
CH	Bos, J. (1989) Cancer Res. 49: 4683-4689
CI	Brummelkamp, T.R. et al. (2002) Cancer Cell 2:243-247
CJ	Dean et al. (1994) J. Biol. Chem. 269:16446-16424
CK	Denouel-Galy, A. et al. (1998) Curr. Biol. 8:46-55
CL	Duff et al. (1995) J. Biol. Chem. 270:7161-7166
CM	Geary, R.S. et al. (1997) Anticancer Drug Des 12:383-393
CN	Genbank Accession No. U43585; ROD 1/30/96
CO	Genbank Accession No. NM _013571; ROD 1/7/02
CP	Gokhale, P.C. et al. (1999) Antisense Nucleic Acid Dru Dev. 9:191-201
CQ	Grant, M.L. et al. (1990) Oncogene 5:1159-1164

EXAMINER:	DATE CONSIDERED:
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	1216-1-006/CIP
		SERIAL NO.	10/727,358
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	Richard N. Kolesnick, et al.
		FILING DATE	December 3, 2003
		GROUP	1635

	CR	Gupta, A.K. et al. (2000) Radiat Res. 154:64-72
	CS	Gupta, A.K. et al. (2001) Cancer Ras 61:4278-4282
	CT	Henry, S.P. et al. (1997) Anticancer Drug Des 12:395-408
	CU	Ho et al. (1996) Nucl Acids Res 24:1901-1907
	CV	Ho et al. (1998) Nature Biotechnology 16:59-630
	CW	Jones, H. et al. (2001) Semin Radiat Oncol. 11:328-337
	CX	Kabanov, et al. (1990) FEBS Lett. 259:327
	CY	Kornfeld, K., Hom, D.B. & Horvitz, H.R. (1995) Cell 83:903-913
	CZ	Kushner, D.M. and Silverman, R.H. (2000) Curr Oncol Rep 2:23-30
	DA	Laptev et al. (1994) Biochem. 33:11033-11039
	DB	Lozano, J. et al (2003) Cancer Research 63:4232-4238
	DC	Migley, R.S. and Kerr, D.J. (2002) Crit Rev Oncol Hematol. 44:109-120
	DD	Mishra et al. (1994) Life Sciences 317:977-982
	DE	Monia et al. (1992) J. Biol. Chem. 267:19954-19962
	DF	McKenna, W.G. (1990) Int J Radiat Oncol Biol Phys 18:849-859
	DG	McKenna, W.G. et al. (1990) Cancer Res 50:97-102
	DH	Nguyen, A. et al. (2002) Mol. Cell Biol. 22:3035-3045
	DI	Ogiso, Y. et al. (1994) Gene Ther 1:403-407

EXAMINER:	DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	1216-1-006/CIP
		SERIAL NO.	10/727,358
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	Richard N. Kolesnick, et al.
		FILING DATE	December 3, 2003
		GROUP	1635

	DJ	Ohmachi, M. et al. (2002) Curr Biol 12:427-433
	DK	Ojala et al (1997) Antisense Nucl Drug Dev. 7:31-38
	DL	Sundaram, M. & Han, M. (1995) Cell 83:889-901
	DM	Therrien, M. et al. (1995) Cell 83:879-888
	DN	Wang et al. (1995) Proc. Natl. Acad. Sci. USA 92:3318-3322
	DO	Xing, H., Kornfeld, K. & Muslin, A.J. (1997) Curr. Biol. 7:294-300
	DP	Xing, H.R., Lozano, J. and Kolesnick, R. (2000) J. Biol. Chem. 275:17267-17280
	DQ	Xing, H.R. and Kolesnick, R. (2001) J. Biol. Chem. 276: 9733-9741
	DR	Xing, H.R. and Kolesnick, R. (2002) Proc. Amer. Assoc. Cancer Res. 43:720 (Abstract #3571)
	DS	Xing, H.R. et al. (2003) Nature Med. 9:1266-1268 (Epub September 7, 2003)
	DT	Xing, H.R. et al. (2003) Proc. Amer. Assoc. Cancer Res. 44(2):192 (Abstract #960)
	DU	Yamagami et al. (1996) Blood 87:2878-2884
	DV	Yao, B. et al. (1995) Nature 378:307-310
	DW	Zhang, Y. et al. (1997) Cell 89:63-72

EXAMINER:	DATE CONSIDERED:
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	